Potential Breakthrough Option For Parkinson’s: LTI Partners With Allergan
January 9, 2017 - 9:40am
Today Allergan announced a transformative deal with Lysosomal Therapeutics (LTI), an emerging biotech focused on Parkinson’s Disease through an understanding of human genetics and sphingolipid biology (here). This deal brings a new chapter for LTI as we move our lead
The post Potential Breakthrough Option For Parkinson’s: LTI Partners With Allergan appeared first on LifeSciVC.
Related StoriesHitting The Milestones: Update On Earning “Biobucks”Beyond Biotech M&A: What Comes ThereafterRiding The Gene Editing Wave: Reflections On
Continue reading this article »